Quotient Sciences, a global drug development and manufacturing accelerator, installed Centillion’s Biofoundry-in-a-Box (BiaB), the first multi-product GMP platform technology for end to end RNA manufacture.
 
BiaB is a modular, integrated, and automated RNA-micro factory designed to enable the end-to-end production of various RNA-based products, including messenger RNA (mRNA) and self-amplifying RNA (saRNA), and has the potential to significantly reduce the time it takes to bring RNA therapies to market.
 
The first of its kind, Centillion’s BiaB technology offers continuous flow-based manufacture and encapsulation of RNA, more flexibility with higher productivities at smaller footprints, according to the company. It also enables larger quantities of RNA drug substance to be split and encapsulated in portions to create a series of RNA-LNPs for preclinical or clinical evaluation.
 
“We are excited to partner with Centillion Technology and install the world’s first GMP Biofoundry-in-a-Box at our Alnwick site,” said Paul Ryan, SVP and Head of Candidate Development at Quotient Sciences. 
 
Harris Makatsoris, CEO at Centillion Technology Ltd. said, “The Biofoundry-in-a-Box is a significant advancement in RNA manufacturing. It is the key component of Centillion’s RNA-by-Design offering, for the delivery of regulatory ready, patient centric and equitable access to advanced therapies. The BiaB enables our mission of a robust response to unmet clinical needs for everyone, everywhere. The BiaB advantages over traditional methods of RNA manufacturing, include high throughput of high-quality pharmaceutical products, aligning with the rapid response needs of manufacturing accelerators as Quotient Sciences. It is efficient, flexible and cost-effective. 
 
“Quotient Sciences is the first CDMO to successfully install and qualify the GMP Biofoundary-in-a-Box system. We’re delighted to be working with them to enable the development of new RNA-based therapies and accelerate the delivery of existing therapies to patients.”
 
Quotient Sciences has been collaborating with Centillion Technology since 2022 to guide and refine features of the Biofoundry-in-a-Box, supported by the Wellcome Leap R3 Program. Quotient Sciences worked with Centillion on operator usability and GMP guidance before the final system was delivered to Quotient Sciences’ Alnwick site in July 2024 to be installed and commissioned.